Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Regulatory Dendritic Cell (DCreg) Therapy in Live-Donor Renal Transplant Recipients
NCT03726307Phase 1Active, not recruiting
- Start
- Apr 2019
- Primary completion
- May 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Regulatory Donor-Derived Dendritic Cell in kidney transplant rejection (3 arms). Primary endpoint: Composite Outcome: Proportion of Participants who Experience any of the Pre-Specified Safety Events at 1 year. Started Apr 2019; status: active, not recruiting.
02
Drugs
Regulatory Donor-Derived Dendritic Cell
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03726307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726307.